The effect of rosiglitazone on the expression of thrombogenic markers on leukocytes in type 2 diabetes mellitus.
Diabetes mellitus is associated with a number of prothrombotic abnormalities, and correction of these abnormalities might translate into the reduction of cardiovascular risk. Glitazones improve endothelial function and reduce inflammation, but much less is known about their effect on thrombogenic factors. We have therefore studied the effect of rosiglitazone on leukocyte and soluble thrombogenic markers in patients with type 2 diabetes mellitus. Thirty-three subjects with type 2 diabetes and 32 normal controls were included; patients were examined at baseline and after 5 months of rosiglitazone treatment (4 mg/day). We measured leukocyte-platelet aggregates and leukocyte expression of either P-selectin glycoprotein ligand 1 (PSGL-1) or receptor for urokinase-type plasminogen activator (uPAR) using flow cytometry, as well as several circulating soluble thrombogenic markers by ELISA method. Leukocyte expression of uPAR and PSGL-1 was significantly higher in patients than in controls. Leukocyte-platelet aggregates and leukocyte expression of uPAR and PSGL-1 significantly decreased after rosiglitazone. There was also significant decrease in CRP and fibrinogen levels, but there was no effect of diabetes and/or rosiglitazone on other circulating molecules. In conclusions, we observed a substantial improvement in the expression of thrombogenic markers on leukocytes after rosiglitazone treatment, suggesting the novel antithrombotic effects of rosiglitazone.
Svobodová
H
H
Third Department of Internal Medicine, First School of Medicine, Charles University, Prague, Czech Republic.
Stulc
T
T
Kasalová
Z
Z
Doležalová
R
R
Marinov
I
I
Capek
P
P
Ceska
R
R
D000368:Aged; D015415:Biomarkers / Q000378:metabolism; D001792:Blood Platelets / Q000502:physiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007962:Leukocytes / Q000378:metabolism* / Q000502:physiology; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008875:Middle Aged; D047495:PPAR gamma / Q000819:agonists; D055293:Receptors, Urokinase Plasminogen Activator / Q000378:metabolism*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013927:Thrombosis / Q000378:metabolism
D015415:Biomarkers; D007004:Hypoglycemic Agents; D008562:Membrane Glycoproteins; C084882:P-selectin ligand protein; D047495:PPAR gamma; D055293:Receptors, Urokinase Plasminogen Activator; D045162:Thiazolidinediones; D000077154:Rosiglitazone